Blog | HemaCare

Hematopoietic Stem Cell Mutations May Lead to Increased Risk for Leukemia and Heart Disease

Feb 23, 2021 10:03:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Cardiovascular Disease, Stem Cells

0 Comments

Two teams of scientists have discovered a set of inherited gene variants that can increase the risk of developing mutations in HSC’s in their lifetimes. The mutations can lead to two different age-related disorders: clonal hematopoiesis of indeterminate potential and myeloproliferative neoplasms. 

Advancing age has been associated with an increased risk of various chronic diseases and conditions. Mutations in hematopoietic stem cells increase as people age and may be linked to an increased risk of leukemia and cardiovascular disease. Somatic mutations in hematopoietic stem cells are connected to the development of myeloproliferative neoplasms (MPN) characterized by an excess of red blood cells, leukocytes, and platelets that leads to an increased susceptibility to develop leukemia.

Read More

HemaCare Macrophages Help Solve Mysteries of Immune Regulation

Jan 26, 2021 10:25:00 AM / by Nancy Andon, MSc posted in Cancer, Macrophages, Immunotherapy (Immunology)

0 Comments

The use of HemaCare-sourced macrophages has been cited in a recent publication in the Journal of Immunology. The paper is a collaboration between the University of Maryland in College Park, and biopharmaceutical company AstraZeneca. [1]

The role of macrophages in the human immune system is not nearly as well-known as T cells or B cells, which are seemingly ubiquitous in the cell and gene therapy field. Like lymphocytes, macrophages are derived from hematopoietic stem cells. Unlike the lymphoid lineage, however, myeloid precursors ultimately produce in the macrophage an immune cell capable of both antigen presentation and phagocytic activity.

Read More

Researchers Discover New Way to Empower T Cells' Anti-Tumor Activity

Jan 5, 2021 10:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, T Cells

0 Comments

Researchers have discovered that the use of antibody blocks TREM2 proteins can empower immune cells and destroy tumors, and eliminate completely in mouse models when they were combined with anti-PD-1 immunotherapy. 

Anti-cancer immunotherapy uses the body’s immune system to destroy tumor cells. Despite breakthroughs in this medical arena, a limited number of patients actually benefit from these therapies. A significant reason for the less-than-desirable responses is tumor cells’ ability to circumvent various T-cell immune mechanisms. Therefore, populations of resistant tumor cells hinder the effectiveness of current immunotherapeutic approaches in many patients.

Read More

Patients with Advanced Bladder Cancer May See Prolonged Survival with Immunotherapy

Dec 1, 2020 10:05:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Immunotherapy (Immunology)

0 Comments

Published in the medical journal New England Journal of Medicine, a study found the proven drug, avelumab, may help the survival rate of those diagnosed with bladder cancer. 

According to the American Cancer Society, the 2020 United States estimates for bladder cancer cases are approximately 81,400 for new cases and 17,980 deaths. However, bladder cancer is a worldwide concern being the 13th most common cancer. Platinum-based chemotherapy is the standard-of-care for advanced urothelial carcinoma. Nevertheless, progression-free and overall survival are minimal with chemotherapy.

Read More

Clinical Trials Begin for CAR-T Immunotherapy for Metastatic Prostate Cancer

Nov 24, 2020 10:03:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, T Cells, NK Cells

0 Comments

Clinical trials have begun with its first round of Metastatic Prostate Cancer patients for immune cell therapy. 

Chimeric antigen receptor T cell (CAR-T) therapy uses the body’s own immune cells to target tumor cells. T cells are taken from a patient’s body then genetically modified to target specific protein markers on tumor cells. As research and development of the next generation of cell therapies continue, new efforts are underway to discover new targets for CAR-T cell development.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts